Article
Medicine, General & Internal
Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W. C. J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosinol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M. J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodriguez-Otero, Joan Blade, Philippe Moreau
Summary: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy showed significant improvement in progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Hematology
Joselle Cook, Isla Johnson, Alexandra Higgins, Surbhi Sidana, Rahma Warsame, Wilson Gonsalves, Morie A. Gertz, Francis Buadi, Martha Lacy, Prashant Kapoor, Angela Dispenzieri, Taxiarchis Kourelis, David Dingli, Amie Fonder, Suzanne Hayman, Miriam Hobbs, Yi Lisa Hwa, Robert Kyle, Nelson Leung, Ronald Go, Vincent S. Rajkumar, Shaji Kumar
Summary: This study retrospectively analyzed 555 newly diagnosed multiple myeloma patients treated with VRd, comparing different schedules of bortezomib administration. While once weekly bortezomib showed better response rates, there was no significant impact on PFS or OS with varying administration schedules.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Oncology
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, Dhwani Patel, Oscar B. B. Lahoud, Heather J. J. Landau, David J. J. Chung, Gunjan L. L. Shah, Michael Scordo, Sergio A. A. Giralt, Alexander Lesokhin, Saad Z. Z. Usmani, Ola Landgren, Neha Korde
Summary: This retrospective study compared the efficacy and safety of VRd and KRd as induction regimens. The results showed that KRd was associated with improved progression-free survival (PFS) and event-free survival (EFS) compared to VRd, with a more significant improvement observed in high-risk patients.
BLOOD CANCER JOURNAL
(2023)
Article
Oncology
Marc-Andrea Baertsch, Mathilde Fougereau, Thomas Hielscher, Sandra Sauer, Iris Breitkreutz, Karin Jordan, Carsten Mueller-Tidow, Hartmut Goldschmidt, Marc-Steffen Raab, Jens Hillengass, Nicola Giesen
Summary: Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) following re-induction treatment with carfilzomib/lenalidomide/dexamethasone (KRd) led to deep remissions and prolonged progression-free survival (PFS) in patients with relapsed and/or refractory multiple myeloma (RRMM). Maintenance treatment post salvage HDCT/ASCT further enhanced PFS, making this a safe and effective strategy for RRMM patients.
Article
Hematology
Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Fritz Offner, Darrell J. White, Lionel Karlin, Lotfi Benboubker, Sophie Rigaudeau, Philippe Rodon, Eric Voog, Sung-Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Philip Twumasi-Ankrah, Godwin Yung, Robert M. Rifkin, Philippe Moreau, Sagar Lonial, Shaji K. Kumar, Paul G. Richardson, S. Vincent Rajkumar
Summary: Continuous treatment with lenalidomide-dexamethasone (Rd) plus ixazomib showed a progression-free survival benefit compared to placebo in transplant-ineligible newly diagnosed multiple myeloma patients. Addition of ixazomib to Rd led to higher rates of complete and very good partial response, especially in high-risk cytogenetics subgroup. The combination therapy was generally well-tolerated with manageable toxicities and no new safety signals observed.
Article
Oncology
Hartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, Natalia Becker, Christina Habermehl, Thomas Hielscher, Marc-Steffen Raab, Jens Hillengass, Sandra Sauer, Carsten Mueller-Tidow, Steffen Luntz, Anna Jauch, Dirk Hose, Anja Seckinger, Peter Brossart, Martin Goerner, Stefan Klein, Martin Schmidt-Hieber, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Haenel, Hans Martin, Hans W. Lindemann, Christoph Scheid, Axel Nogai, Hans Salwender, Richard Noppeney, Britta Besemer, Katja Weisel
Summary: The efficacy of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) has not been clearly defined in the era of continuous novel agent treatment, however, patients who received this treatment may have benefited.
Article
Oncology
Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R. Dholaria, Timothy M. Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhaka, Susan Bal, Smith Gid, Anita D'Souza, Aric Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Had, Natalie S. Callander
Summary: Dara-KRd, AHCT, and MRD response-adapted consolidation lead to a high rate of MRD negativity in NDMM patients. This strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance for patients with 0 or 1 HRCA.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Thierry Facon, Gordon Cook, Saad Z. Usmani, Cyrille Hulin, Shaji Kumar, Torben Plesner, Cyrille Touzeau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Hartmut Goldschmidt, Hang Quach, Mohamad Mohty, Christopher P. Venner, Katja Weisel, Noopur Raje, Benjamin Hebraud, Karim Belhadj-Merzoug, Lotfi Benboubker, Olivier Decaux, Salomon Manier, Denis Caillot, Jon Ukropec, Huiling Pei, Rian Van Rampelbergh, Clarissa M. Uhlar, Rachel Kobos, Sonja Zweegman
Summary: In patients with transplant-ineligible newly diagnosed multiple myeloma, the combination of daratumumab plus lenalidomide/dexamethasone improved progression-free survival compared to lenalidomide/dexamethasone alone. This benefit was observed regardless of patients' frailty status. Daratumumab showed improved response rates and minimal residual disease negativity across subgroups.
Article
Hematology
Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Clara Mariette, Lotfi Benboubker, Denis Caillot, Cecile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hebraud, Jill Corre, Michel Attal
Summary: The study shows that using carfilzomib, lenalidomide, and dexamethasone in combination with transplant treatment for eligible patients with newly diagnosed multiple myeloma can produce rapid and deep responses, with an acceptable safety profile. Close monitoring of cardiovascular adverse events is necessary.
Article
Oncology
Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, Luca Bertamini, Angelo Belotti, Monica Galli, Massimo Offidani, Elena Zamagni, Antonio Ledda, Mariella Grasso, Stelvio Ballanti, Antonio Spadano, Michele Cea, Francesca Patriarca, Mattia D'Agostino, Andrea Capra, Nicola Giuliani, Paolo de Fabritiis, Sara Aquino, Angelo Palmas, Barbara Gamberi, Renato Zambello, Maria Teresa Petrucci, Paolo Corradini, Michele Cavo, Mario Boccadoro
Summary: This study aimed to evaluate the efficacy and safety of different carfilzomib-based treatment approaches and maintenance therapy, showing that KRd plus ASCT demonstrated superiority in improving responses compared with other treatments, and carfilzomib plus lenalidomide as maintenance therapy improved progression-free survival compared with lenalidomide alone.
Article
Oncology
Shanhao Tang, Yin Lu, Pisheng Zhang, Dong Chen, Xuhui Liu, Xiaohong Du, Junjie Cao, Peipei Ye, Lieguang Chen, Shuangyue Li, Keya Sha, Xian Xu Zhuang, Yiyu Xie, Xiaojin Wu, Renzhi Pei
Summary: The study analyzed 252 cases of newly diagnosed MM and found that the VRD induction chemotherapy group had a significantly higher overall response rate than the non-VRD group. Tandem-ASCT was shown to significantly improve the prognosis of multi-hit MM.
Article
Hematology
Peter A. Forsberg, Adriana C. Rossi, Angelique Boyer, Roger N. Pearse, Karen A. Pekle, David Jayabalan, Stephanie Lakritz, Kari Flicker, Drew Ribadeneyra, Brielle Liotta, Scott Ely, Leora Boussi, John N. Allan, Morton Coleman, Ruben Niesvizky, Tomer M. Mark
Summary: The study evaluated a new treatment regimen for multiple myeloma called Car-BiRd and found that it can achieve similar outcomes with reduced toxicities compared to standard treatment regimens. The results showed a high overall response rate in newly diagnosed MM patients and suggest that the sequential Car-BiRd regimen is an effective and safe approach for upfront treatment.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Oncology
Thierry Facon, Shaji K. Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Joseph R. Mace, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Tahamtan Ahmadi, Jianping Wang, Rian Van Rampelbergh, Clarissa M. Uhlar, Brenda Tromp, Maria Delioukina, Jessica Vermeulen, Saad Z. Usmani
Summary: In patients with newly diagnosed multiple myeloma who are ineligible for stem-cell transplantation, daratumumab plus lenalidomide and dexamethasone significantly improved overall survival and progression-free survival with no new safety concerns.
Article
Oncology
Dominik Dytfeld, Tomasz Wrobel, Krzysztof Jamroziak, Tadeusz Kubicki, Pawel Robak, Adam Walter-Croneck, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Adam Nowicki, Tomasz Szczepaniak, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Pula, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Lukasz Szukalski, Agnieszka Konska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Oscar B. Lahoud, Jeffrey A. Zonder, Kent Griffith, Andrew Stefka, Ajay Major, Benjamin A. Derman, Andrzej J. Jakubowiak
Summary: This study compared the efficacy and safety of maintenance therapy with carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone in patients with newly diagnosed multiple myeloma. The results showed that the combination therapy group had longer progression-free survival compared to the lenalidomide monotherapy group. Further research is needed to confirm these findings.
Article
Oncology
Zhongjun Huo, Fang Chen, Ping Liu, Zimian Luo
Summary: This study compares the response and safety of Ixazomib/Lenalidomide/Dexamethasone (IRd) and Bortezomib/Lenalidomide/Dexamethasone (VRd) treatments in newly diagnosed multiple myeloma. The results show that IRd has similar efficacy to VRd, but with better safety and may be more suitable for patients with poor baseline conditions.
Article
Hematology
Aldo A. Acosta-Medina, Ann M. Moyer, Ronald S. Go, Maria Alice V. Willrich, Fernando C. Fervenza, Nelson Leung, Christianne Bourlon, Jeffrey L. Winters, Grant M. Spears, Sandra C. Bryant, Meera Sridharan
Summary: Eculizumab is effective for complement-mediated thrombotic microangiopathy. Discontinuation of therapy does not universally lead to relapse. This study aimed to assess the role of complement genetic variants in predicting recurrence after Eculizumab withdrawal. A total of 280 patients were included, with CFH and MCP/CD46 being the most commonly identified genetic variants. The relapse rate after discontinuation was 29.6%, with CFH and MCP/CD46 variants in canonical splice regions having the highest relapse rates.
Article
Biochemistry & Molecular Biology
Nadine Abdallah, Angela Dispenzieri, Eli Muchtar, Francis K. K. Buadi, Prashant Kapoor, Martha Q. Q. Lacy, Yi L. L. Hwa, Amie Fonder, Miriam A. A. Hobbs, Suzanne R. R. Hayman, Nelson Leung, David Dingli, Ronald S. S. Go, Yi Lin, Wilson I. I. Gonsalves, Moritz Binder, Taxiarchis Kourelis, Rahma Warsame, Robert A. A. Kyle, S. Vincent Rajkumar, Morie A. A. Gertz, Shaji K. K. Kumar
Summary: After long-term follow-up, there is no clear evidence to support the benefit of doxycycline in the post-transplant setting.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
(2023)
Article
Oncology
Bharat Nandakumar, Francis Baffour, Nadine H. H. Abdallah, Shaji K. K. Kumar, Angela Dispenzieri, Francis K. K. Buadi, David Dingli, Martha Q. Q. Lacy, Suzanne R. R. Hayman, Prashant Kapoor, Nelson Leung, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Eli Muchtar, Rahma Warsame, Taxiarchis V. V. Kourelis, Ronald S. S. Go, Robert A. A. Kyle, Morie A. A. Gertz, S. Vincent Rajkumar, Jason Klug, Panagiotis Korfiatis, Wilson I. I. Gonsalves
Summary: Using a deep learning-based segmentation approach, sarcopenia can be accurately detected and measured in clinical computed tomography (CT) images of patients with newly diagnosed multiple myeloma (NDMM). Sarcopenia significantly affects overall survival in NDMM patients and is an independent adverse prognostic factor.
Editorial Material
Oncology
Jean-Sebastien Claveau, David L. Murray, Angela Dispenzieri, Prashant Kapoor, Moritz Binder, Francis Buadi, David Dingli, Amie Fonder, Morie Gertz, Wilson Gonsalves, Suzanne Hayman, Miriam Hobbs, Yi Lisa Hwa, Taxiarchis Kourelis, Martha Lacy, Nelson Leung, Yi Lin, Rahma Warsame, Robert A. Kyle, Vincent Rajkumar, Shaji K. Kumar
Article
Oncology
Hila Fishov, Eli Muchtar, Mali Salmon-Divon, Angela Dispenzieri, Tal Zvida, Claudio Schneider, Benjamin Bender, Adrian Duek, Merav Leiba, Ofer Shpilberg, Oshrat Hershkovitz-Rokah
Summary: This study examines the specific miRNA expression profile in AL-amyloidosis and its involvement in the disease's pathogenesis. The downregulation of miR-9-5p and miR-181a-5p induces anti-apoptotic mechanisms in AL-amyloidosis, suggesting their potential as tumor-suppressors. The study also highlights the potential use of BCL-2 inhibitors in treating this disease.
Article
Urology & Nephrology
Naba Farooqui, Mark Zaidi, Lisa Vaughan, Trevor D. McKee, Eram Ahsan, Kevin D. Pavelko, Jose C. Villasboas, Svetomir Markovic, Timucin Taner, Nelson Leung, Haidong Dong, Mariam P. Alexander, Sandra M. Herrmann
Summary: This study found that immune checkpoint inhibitors (ICIs) therapy may lead to acute kidney injury (AKI) and there are no biomarkers currently available to distinguish AKI caused by ICIs from other causes. The urine levels of cytokines such as TNF-a, IL-2, and IL-10 were significantly higher in AKI-ICI patients. Therefore, these T-cell responses and their respective cytokines may be helpful in differentiating AKI-ICI from AKI-other.
KIDNEY INTERNATIONAL REPORTS
(2023)
Letter
Hematology
Nate Gipe, Nelson Leung, Terra Lasho, Abhishek Mangaonkar, Hassan Alkhateeb, Aref Al-Kali, Naseema Gangat, William Hogan, Kristen McCullough, Ayalew Tefferi, Mariam Priya Alexander, Mrinal M. Patnaik
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Nelson Leung, S. Vincent Rajkumar
Summary: Light chain cast nephropathy (LCCN) is a significant cause of acute kidney injury (AKI) in patients with multiple myeloma (MM) and is now considered as a defining event of myeloma. While long-term prognosis has improved, short-term mortality remains higher in patients with LCCN if renal failure is not reversed. Rapid reduction of involved serum free light chain is critical for renal function recovery. Treatment algorithm for MM patients with biopsy-proven LCCN or ruling out other causes of AKI is provided based on randomized trial data whenever available. Clinical trial enrollment is recommended prior to following the treatment algorithm.
BLOOD CANCER JOURNAL
(2023)
Article
Oncology
Alexander J. Ryu, Shaji Kumar, Angela Dispenzieri, Robert A. Kyle, S. Vincent Rajkumar, Thomas C. Kingsley
Summary: This study used machine learning and electronic health record data to identify potential drug candidates for modifying the progression risk of MGUS. Various medications were found to be significantly associated with the risk of MGUS progression, which could inform future prospective studies.
BLOOD CANCER JOURNAL
(2023)
Letter
Hematology
Eli Silvert, Laura Hester, Eshwan Ramudu, Colin Pawlowski, Britte Kranenburg, Francis Buadi, Eli Muchtar, Samer Khaled, Namphuong Tran, Venky Soundararajan, Najat Khan, Morie Gertz, Angela Dispenzieri
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Letter
Hematology
Samuel R. Kosydar, Sameer A. Parikh, Scott C. Lester, Kari G. Rabe, Wei Ding, Jessica F. Burlile, Saad S. Kenderian, Yucai Wang, Eli Muchtar, Amber B. Koehler, Susan M. Schwager, Susan L. Slager, Neil E. Kay, Timothy G. Call, William G. Breen, Paul J. Hampel
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Letter
Oncology
Rahul Banerjee, Bo Wang, Larry D. Anderson, Georgia Mccaughan, Nikita Mehra, Andrew J. Cowan, S. Vincent Rajkumar, Gurbakhash Kaur
BLOOD CANCER JOURNAL
(2023)
Editorial Material
Urology & Nephrology
Sheron Latcha, Nelson Leung
Article
Urology & Nephrology
Jason N. Barreto, Erin F. Barreto, Kristin C. Mara, Andrew D. Rule, John C. Lieske, Callen D. Giesen, Carrie A. Thompson, Nelson Leung, Thomas E. Witzig, Kianoush B. Kashani